53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

Study Purpose

53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs.#46;Placebo in Subjects with Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 50 Years - 80 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria.Volunteers will be included in the study only if they satisfy all the following criteria: 1. Able to read, understand, sign, and date the subject informed consent. 2. Have given written informed consent before any study-related activities are carried out and are able to understand the nature and purpose of the trial, including possible risks and adverse effects. 3. Adult males and females, 50 to 80 years of age (inclusive) at Screening. 4. Body weight less than 136 kgs (300 lbs) at Screening. 5. Except for OA, subject is medically healthy (in the opinion of the PI), as determined by prestudy medical history, and without clinically significant abnormalities including: 1. Clinically relevant findings on physical examination that would preclude trial compliance. 2. Heart rate <40 BPM or >100 BPM after 5 minutes rest in supine or semi-supine position. 3. Body temperature <95.9°F or >99.8°F. Note: The above assessments may be repeated, if abnormal values are recorded in the first instance, at the discretion of the Investigator (or delegate). 6. Available X-Ray of target knee obtained within 12 months prior to Screening with radiographic evidence of osteoarthritis in the medial and/or lateral tibio-femoral compartment; KL grading is not required. 7. Clinical diagnosis of knee OA with at least 2 of the 4 following signs/symptoms in the target knee, and in the absence of palpable warmth suggesting synovitis or infection:

  • - Crepitus on knee extension.
  • - Bony tenderness.
  • - Bony enlargement.
  • - Morning stiffness in target knee <30 minutes.
8. Stability of Cruciate and collateral ligaments as defined by clinical examination (e.g. tests such as Lachman, pivot shift, posterior drawer, posterior sag, valgus and Varus stress). 9. Results of the KOOS Knee Survey Screening Questionnaire performed at Screening for the target knee that indicate either: moderate or greater difficulty in at least 5 of 17 questions (A1-17) in the "Function, daily living" subsection; or a total score of at least 20/68 in that subsection. 10. Results of the KOOS Knee Survey Screening Questionnaire performed at Screening that indicate moderate or greater pain on question P6 "pain going up or down stairs" in the target knee. 11. Willing to use only acetaminophen (Tylenol® or equivalent), hydrocodone, orhydrocodone/acetaminophen (e.g., Norco® or equivalent) for breakthrough pain during the4-week injection period. The maximum dose of acetaminophen from all sources must not exceed 4000 mg/day. 12. Willing NOT to use non-steroidal anti-inflammatory drugs such as aspirin, ibuprofen (Motrin® or equivalent), or naproxen (Aleve® or equivalent) during the 4-week injection period. 13. Willing NOT to use approved or investigational IA products for knee OA for the duration of participation in the study. 14. If using GLP-1 medications such as Wegovy® or similar, must be on a stable dose for at least 2 months prior to Screening. 15. Female subjects of childbearing potential who are sexually active (non-abstinent) must agree to and comply with using 2 highly effective methods of birth control (oral contraceptive implant, injectable or indwelling intrauterine device, condom with spermicide or sexual abstinence) while participating in the study. Male participants must agree to use a barrier contraception method to prevent pregnancy, and agree not to donate sperm from the time of the first injection through the end of the study. 16. Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions. 17. MRI Screening: Tibio-femoral osteoarthritis with MRI based femoral B-score at Screening of 0.5 or greater in at least one knee as determined by central analysis. Exclusion Criteria.Subjects are excluded from the study if any of the following criteria are met: 1. Contraindication to MRI. 2. Demonstrated clinically significant (required intervention, e.g., emergency room visit, epinephrine administration) allergic reactions (e.g., food, drug, or atopic reactions, asthmatic episodes) which, in the opinion of the Investigator, would interfere with the volunteer's ability to participate in the trial. 3. Prior surgery in the target knee, excluding procedures for debridement only (no previous micro-fracture procedure). 4. Knee joint replacement or any other knee surgery planned in either knee while participating in the study. 5. Moderate or severe pain in the contralateral (non-target) knee. 6. History of fibromyalgia, rheumatoid arthritis (RA), psoriatic arthritis, or any other autoimmune or infectious cause for arthritis; or referred knee pain from hip or spinal disease. 7. Knee effusion >2+ on the following clinical scale: 1. Zero = No wave produced on down stroke. 2. Trace = Small wave on medial side with down stroke. 3. 1+ = Larger bulge on medial side with down stroke. 4. 2+ = Effusion spontaneously returned to medial side after upstroke (no down stroke necessary) 5. 3+ = So much fluid that it was not possible to move the effusion out of the medial aspect of the knee. 8. Last viscosupplementation (e.g., Synvisc® or similar hyaluronic acid product) injected into either knee < 3 months before Screening. 9. Last IA injection of corticosteroids < 2 months before Screening. 10. Current (within previous month before Screening) of use of any systemic steroids (except inhaled corticosteroids for allergy or respiratory problems). 11. Known hypersensitivity to any of the study drug ingredients. 12. Known hypersensitivity to acetaminophen or hydrocodone. 13. History of arthroscopy in the target knee in the 3 months before Screening. 14. History of septic arthritis, gout, or pseudo-gout in either knee in the year before Screening. 15. Clinical signs in the opinion of the Investigator of acute meniscal tear (e.g. locking or acute mechanical signs or symptoms consistent with meniscal tear) in either knee. 16. Skin lesion, rash, infection, or hypersensitivity in the target knee at or near the injection site at Screening. 17. Bleeding problems, platelet or coagulation deficiency that, in the option of the Investigator, contraindicates IA injection. 18. Active systemic infection at Screening or immediately pre-dose on any IA injection day, including chronic viral infection. 19. Current treatment or treatment within 2 years prior to Screening for any malignancy except basal cell or squamous cell carcinoma of the skin, prostate or cervical cancer in situ, unless with specific written permission provided by the Sponsor's Medical Monitor. 20. Women of childbearing potential who are pregnant, nursing, or planning to become pregnant, and women or men who do not agree to remain on an acceptable method of birth control throughout the entire study period. 21. Participation in other clinical OA drug studies within 1 year prior to Screening except epidemiologic studies involving no drug treatment. 22. Any participation in other clinical OA stem cell or gene therapy studies. 23. Currently taking paclitaxel (mitotic inhibitor), natalizumab (anti-integrin monoclonal antibody), or any other anti-integrin treatment. 24. Routine consumption of more than 3 alcoholic drinks a day (definition of 1 alcoholic drink:
  • - 12-ounces of beer, 8-ounces of malt liquor, 5-ounces of wine, 1.5- ounces or a "shot" of 80-proof distilled spirits or liquor such as gin, rum, vodka, or whiskey).
25. History of substance abuse in the opinion of the Investigator within the two years prior to Screening.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT06865079
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

OrthoTrophix, Inc
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Dawn McGuire - Chief Medical Officer, M.D. FAAN
Principal Investigator Affiliation OrthoTrophix, Inc
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Osteoarthritis (OA) of the Knee
Additional Details

This multicenter, double-blind, placebo controlled, randomized study is designed to investigate the safety and efficacy of TPX-100 administered in 4 weekly doses of 200 mg per dose in subjects with tibio-femoral osteoarthritis. The B-score as determined by MRI analysis is the final inclusion criteria, which will be determined by MRI-based assessment. A standardized screening MRI will be obtained on otherwise eligible candidates. For enrolled subjects, the Screening MRI will serve as the Baseline MRI. Enrolled subjects will be assigned randomly to receive either TPX-100 or PBS placebo, 4 weekly IA injections administered into the target knee by fluoroscopy or ultrasound guidance. Subjects will undergo follow-up knee MRIs at Week 27 and Week 53 after the first injection. All MRIs will be read by computer-based, standardized methods, blind to treatment assignment and temporal sequence, to provide the imaging outcome measures. Subjects will complete PROs at Week 1 (Baseline), Week 27 and Week 53. A clinical safety evaluation will be performed at Week 13, and a safety tele-visit or telephone call will be performed at Week 36. Adverse events, regardless of causation, and concomitant medications will be documented at all study visits and at the Week 37 tele-visit/telephone call. Clinical laboratory assessments will be obtained at Screening, Baseline (Week 1), and Weeks 2, 3, 4; and at the in-person follow up visits. All enrolled subjects will be assigned randomly to receive either TPX-100 or PBS placebo, in 4 weekly IA injections administered into the target knee by fluoroscopy or ultrasound guidance.

Arms & Interventions

Arms

Experimental: TPX-100 (200 mg per dose)

TPX-100 (200 mg per dose) for intra-articular injection administered once-weekly (Week 1, 2, 3 and 4) to a single target knee of the subject for 4 injections.

Placebo Comparator: Placebo / PBS

PBS placebo for intra-articular injection administered once-weekly (Week 1, 2, 3 and 4) to a single target knee of the subject for 4 injections.

Interventions

Drug: - TPX-100 200 mg 4 times weekly for 4 weeks

TPX-100 (200 mg per dose) will be administered once-weekly (Week 1, 2, 3 & 4) to a single target knee of the subject for 4 injections. TPX-100 can be administered by conventional methods such as subcutaneous or intra-articular injection.

Other: - PBS

PBS / placebo for intra-articular injection administered once-weekly (Week 1, 2, 3 and 4) to a single target knee of the subject for 4 injections

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

AMR Mobile, Mobile, Alabama

Status

Not yet recruiting

Address

AMR Mobile

Mobile, Alabama, 36608

Site Contact

Channa Harrison, Site Coordinator

[email protected]

251-414-1984

Elite Clinical Network, Scottsdale, Arizona

Status

Not yet recruiting

Address

Elite Clinical Network

Scottsdale, Arizona, 85260

Site Contact

Hector Calderon, Site Coordinator

[email protected]

480-420-7681

Noble Clinical Research, Tucson, Arizona

Status

Not yet recruiting

Address

Noble Clinical Research

Tucson, Arizona, 85704

Site Contact

Liane Encinas, Site Coordinator

[email protected]

520-612-7860

Legent Orthopedic Hospital, Carrolton, California

Status

Not yet recruiting

Address

Legent Orthopedic Hospital

Carrolton, California, 75006

Site Contact

Jennifer Ruiz, Site Coordinator

[email protected]

469-210-8838

Medvin Clinical Research, Covina, California

Status

Not yet recruiting

Address

Medvin Clinical Research

Covina, California, 91722

Site Contact

Swati Bhalla, Site Coordinator

[email protected]

626-869-5370

CORE Orthopaedic Medical Center, Encinitas, California

Status

Not yet recruiting

Address

CORE Orthopaedic Medical Center

Encinitas, California, 92024

Site Contact

Farouk Awad, Site Coordinator

[email protected]

760-943-6700 #162

Huntington Beach, California

Status

Not yet recruiting

Address

Marvel Clinical Research (Elite Clinical Network)

Huntington Beach, California, 92647

Site Contact

Matt Campos, Site Coordinator

[email protected]

714-375-5970

Medvin Clinical Research Center, Riverside, California

Status

Not yet recruiting

Address

Medvin Clinical Research Center

Riverside, California, 92518

Site Contact

Naomi Lupercio-Orozco Site Coordinator

[email protected]

951-924-6500

Medvin Clinical Research Center, Tujunga, California

Status

Not yet recruiting

Address

Medvin Clinical Research Center

Tujunga, California, 91042

Site Contact

Daniela Castellanos, Site Coordinator

[email protected]

213-281-5146

Medvin Clinical Research Center, Whittier, California

Status

Not yet recruiting

Address

Medvin Clinical Research Center

Whittier, California, 90602

Site Contact

Ligia Rosas, Site Coordinator

[email protected]

562-758-6600 #5

AMR Miami, Coral Gables, Florida

Status

Not yet recruiting

Address

AMR Miami

Coral Gables, Florida, 33134

Site Contact

Olga Acosta, Site Coordinator

[email protected]

305-445-5637

K2 Medical Research, Maitland, Florida

Status

Not yet recruiting

Address

K2 Medical Research

Maitland, Florida, 32751

Site Contact

Carlos Baez, Site Coordinator

[email protected]

407-500-5252

Hope Research Network, Medley, Florida

Status

Not yet recruiting

Address

Hope Research Network

Medley, Florida, 33166

Site Contact

Jose Rafael Gonzalez, Site Coordinator

[email protected]

786-953-8858

Wellness Research Center, Miami, Florida

Status

Not yet recruiting

Address

Wellness Research Center

Miami, Florida, 33135

Site Contact

Damian Sosa, Site Coordinator

[email protected]

786-238-7099

Well Pharma Medical Research, Miami, Florida

Status

Recruiting

Address

Well Pharma Medical Research

Miami, Florida, 33173

Site Contact

Michelle De La Cruz, Site Coordinator

[email protected]

305-665-4818 #212

Las Mercedes Medical Research, Miami, Florida

Status

Not yet recruiting

Address

Las Mercedes Medical Research

Miami, Florida, 33196

Site Contact

Ariadna Zarzuela

[email protected]

786-577-5977 #5001

Drug Studies of America, Marietta, Georgia

Status

Not yet recruiting

Address

Drug Studies of America

Marietta, Georgia, 30060

Site Contact

Tanya Astorga, Site Coordinator

[email protected]

678-581-5252

AMR Kansas City, Kansas City, Kansas

Status

Not yet recruiting

Address

AMR Kansas City

Kansas City, Kansas, 64114

Site Contact

Eric Halleran, Site Coordinator

[email protected]

816-943-0770

University of Kansas Medical Center, Kansas City, Kansas

Status

Not yet recruiting

Address

University of Kansas Medical Center

Kansas City, Kansas, 66160

Site Contact

Jeannine Nilges, Site Coordinator

[email protected]

323-594-6184

AMR Lexington, Lexington, Kentucky

Status

Not yet recruiting

Address

AMR Lexington

Lexington, Kentucky, 40509

Site Contact

Brittany Wilson, Site Coordinator

[email protected]

859-264-8999

Mayo Clinic (Rochester), Rochester, Minnesota

Status

Not yet recruiting

Address

Mayo Clinic (Rochester)

Rochester, Minnesota, 55905

Site Contact

Dave Sejal, Site Coordinator

[email protected]

507-266-9085

Las Vegas Clinical Trials, North Las Vegas, Nevada

Status

Not yet recruiting

Address

Las Vegas Clinical Trials

North Las Vegas, Nevada, 89030

Site Contact

Brianna Catallini, Site Coordinator

[email protected]

702-637-3223

Albuquerque Clinical Trials, Albuquerque, New Mexico

Status

Not yet recruiting

Address

Albuquerque Clinical Trials

Albuquerque, New Mexico, 87102

Site Contact

Valerie Escudero

[email protected]

505-224-7407 #260

Hightower Clinical, Oklahoma City, Oklahoma

Status

Not yet recruiting

Address

Hightower Clinical

Oklahoma City, Oklahoma, 73102

Site Contact

Megan Whitson, Site Coordinator

[email protected]

405-420-4689

University Orthopedics Center, Altoona, Pennsylvania

Status

Not yet recruiting

Address

University Orthopedics Center

Altoona, Pennsylvania, 16602

Site Contact

Penny Adams, Site Coordinator

[email protected]

510-488-3832

University Orthopedics Center, State College, Pennsylvania

Status

Not yet recruiting

Address

University Orthopedics Center

State College, Pennsylvania, 16801

Site Contact

Jill Fremberg, Site Coordinator

[email protected]

814-272-3751

AMR Knoxville, Knoxville, Tennessee

Status

Not yet recruiting

Address

AMR Knoxville

Knoxville, Tennessee, 37909

Site Contact

Elena Pintoc, Site Coordinator

[email protected]

865-410-8300

Accurate Clinical Research, LLC, Baytown, Texas

Status

Not yet recruiting

Address

Accurate Clinical Research, LLC

Baytown, Texas, 77521

Site Contact

Mariela Martinez, Site Coordinator

[email protected]

832-705-7839

Texas Orthopedic Specialist, Bedford, Texas

Status

Not yet recruiting

Address

Texas Orthopedic Specialist

Bedford, Texas, 76021

Site Contact

Amber Morgan, Site Coordinator

[email protected]

817-510-4022

First Surgical Hospital, Bellaire, Texas

Status

Not yet recruiting

Address

First Surgical Hospital

Bellaire, Texas, 77401

Site Contact

Emilio Portillo, Site Coordinator

[email protected]

713-367-8548

Accurate Clinical Research, Houston, Texas

Status

Not yet recruiting

Address

Accurate Clinical Research

Houston, Texas, 77089

Site Contact

Yanet Martinez, Site Coordinator

[email protected]

281-481-8557

CenExel, Salt Lake City, Utah

Status

Not yet recruiting

Address

CenExel

Salt Lake City, Utah, 84107

Site Contact

Scott Zunkowski, Site Coordinator

[email protected]

801-261-2000 #2322

Wasatch Clinical Research, Salt Lake City, Utah

Status

Not yet recruiting

Address

Wasatch Clinical Research

Salt Lake City, Utah, 84107

Site Contact

Karen George, Site Coordinator

[email protected]

801-288-0607